China Recombinant Protein Drugs Market to Hit RMB40 Billion in 2014

DALLAS, November 19, 2014 /PRNewswire/ --

RnRMarketResearch.com adds China Recombinant Protein Drug Industry Report, 2014-2017 market research that says during 2005-2013, sales of recombinant protein drugs available in Chinese sample hospitals grew at a CAGR of 19.1%, and it is projected that China will see its actual demand for recombinant protein drugs exceed RMB40 billion in 2014. The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. Complete report is available at http://www.rnrmarketresearch.com/china-recombinant-protein-drug-industry-report-2014-2017-market-report.html .

The start of recombinant protein drugs industry in China is not late and common drugs are diversified in variety, for example, recombinant human erythropoietin (rhEPO), recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human interferon (rhIFN) have gained market approval in the 1990s. Moreover, in 2013, domestic rhG-CSF, rhEPO and recombinant human growth hormone (rhGH) with price advantage took a respective share of 82.1%, 88.5% and 90.2% in Chinese sample hospitals, and recombinant human interleukin-2/11(rhIL-2/11) was fully localized.

However, as compared with products from leading bio-pharmaceutical enterprises in the United States and Europe, domestic recombinant protein drugs are still characterized by low-end technologies and largely remain in common short-acting areas. And foreign brands still prevail in the markets of recombinant insulin, rhIFN, recombinant coagulation factor and recombinant human follicle-stimulating hormone (rhFSH).

1. Recombinant Insulin Market. In 2013,foreign brands such as Novo Nordisk's insulin as part and insulin detemir, Sanofi's insulin glargine, Eli Lilly's insulin lispro accounted for 91.4% of recombinant insulin market of Chinese sample hospitals, while domestic insulin e.g. insulin glargine and insulin lispro of Gan & Lee Pharmaceuticals, recombinant insulin of Tonghua Dongbao Pharmaceutical and animal insulin of Wanbang Biopharmaceuticals was at a distinct disadvantage, whereas insulin analog products of Gan & Lee are still in the process of development, with huge potential for growth in the future.

2. rhIFN-αMarket.Roche's PEG-IFNα-2a, MSD's PEG-IFNα-2a and IFN-α-2a, and other imported products still dominate Chinese interferon market, sweeping as much as 70.7% of recombinant interferon market of sample hospitals in 2013; whilemore than a dozen local companies like Shanghai Huaxin High Biotechnology Inc., Beijing Tri-Prime Genetic Engineering Co., Ltd. and Anhui Anke Biotechnology (Group) Co., Ltd. mainly produce ordinary short-acting products, which lack strong competitiveness compared with PEG-Intron products (long-acting interferon)with better anti-hepatitis virus effect.

Moreover, there is no domestic recombinant protein drug in such markets as rhIFN-β, rhFSH, recombinant coagulation factor VIIa and factor VIII yet.

Based on support from favorable policies, R&D ability enhancement as well as being optimistic about market prospects, a large number of biotech companies are vigorously developing long-acting, high-end protein drugs.

In August 2014, PEG-rhGHof GeneScience Pharmaceuticals Co., Ltd. (GenSci, a subsidy of Changchun High & New Technology Industry (Group) Inc.) obtained the GMP certificate and could formally go on sale; however, as PEG-rhGH belongs to national new First-in-Class drugs, a phase IV clinical trial is a must, and mass production is expected to begin in 2016. In June 2014, Anke Biotechnology's PEG-rhIFNαand Dongbao Pharmaceutical' sultrolente insulin (insulin glargine) were both approved for clinical application. So far, PEG-GCSF of Jiangsu Hengrui Medicine Co., Ltd., PEG-rhIFNαof Xiamen Amoy top Biotech Co., Ltd. (a subsidiary of Dongbao Pharmaceutical) and rhFSH of GenSci have all declared for production and are expected to be approved and available on the market in 2015.

Companies profiled in this Chinese recombinant protein drug market report include 3SBio Inc., Uni-Bio Science Group Limited, Shenzhen Neptunus Interlong Bio-Technique Co. Ltd., Essex Bio-Technology Limited, Livzon Pharmaceutical Group Inc., Changchun High & New Technology Industry (Group) Inc., Anhui Anke Biotechnology (Group) Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Beijing SL PHarmaceutical Co., Ltd. and Jiangsu Shihuan Bioengineering Co., Ltd. Order a copy of this research at http://www.rnrmarketresearch.com/contacts/purchase?rname=242727 .

China Recombinant Protein Drug Industry Report, 2014-2017 highlights: 

• Market size, competition pattern, market segments, prospects, etc. of recombinant protein drugs worldwide;
• Market situation, competition pattern, R&D, forecasts for2014-2017, etc. of recombinant protein drugs in China;
• Development status, competition pattern, prospects, etc. of product segments e.g. recombinant insulin, rhG-CSF, rhEPO, rhGH, rhFSH in China;
• Operation, recombinant protein drug business, forecast, etc. of 10 keyrecombinant protein drug enterprises in China (including Anhui Anke Biotechnology (Group) Co., Ltd., 3SBio Inc., Livzon Pharmaceutical Group Inc., Tonghua Dongbao Pharmaceutical Co., Ltd., etc.).

Partial list of charts provided in this report include:

Revenue and Net Income of SL Pharm, 2014-2017E

Revenue and Net Income of Dongbao Pharmaceutical, 2014-2017E

Revenue and Net Income of Anhui Anke Biotechnology, 2014-2017E

Revenue and Net Income of Changchun High&New Technology, 2014-2017E

R&D of Major Interferon Products in China as of end-Sept. 2014
Competition Patternof rhG-CSF of Sample Hospitals in China (by Enterprise), 2013
Diseases Lethal to Rural Residents in China, 2012
R&D of Major PEG-rhG-CSF in China as of end-Sept. 2014
Costs of Treatment with Major FSH Products in China, 2012-2014
Competition Patternof FSH of Sample Hospitals in China (by Enterprise), 2013
Costs of Treatmentwith Major EPO Products in China
Market Competition Pattern of rhGH of Sample Hospitals in China (by Enterprise), 2013
Costs of Treatment with Major rhGH Products in China, 2012-2014

Revenue and Net Income of Shihuan Bioengineering, 2014-2017E
Comparison among Sales Growth Rates of Major Recombinant Protein Drugs of Sample Hospitals in China, 2005-2013
Market Competition of Various Genetically Engineered Drugs in China, as of end-Sep.2014
R&D of High-end Recombinant Protein Drugs in China (Partial), as of Sep.2014

The report on Opioids Market Overview to 2023 - Opioids in Western Europe provides an estimation of 2013 opioid revenues and forecast consumption and revenues until 2023 in the five major Western European countries: the UK, Germany, France, Italy and Spain. The estimated revenues for 2013 are highest in the UK, which held a share of 52%, followed by Germany with 20%. Spain had the lowest in terms of both consumption (3.3%) and revenues (2.2%).

Explore more reports on the pharmaceuticals industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals and the biotechnology market at http://www.rnrmarketresearch.com/reports/life-sciences/biotechnology .

About Us: 

RnRMarketResearch.com is an online database of market research reports and in-depth studies of over 5000 micro markets. Not limited to any one industry, we offer research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
sales@rnrmarketresearch.com